ASRS 2023: Nancy Lurker of EyePoint Pharmaceuticals provides update on the Phase 1 DAVIO Trial of EYP-1901

News
Video

At the 2023 ASRS annual meeting, Nancy Lurker, Executive Vice-Chair of the Board of EyePoint Pharmaceuticals, discussed the subgroup analyses of the Phase 1 DAVIO Trial of EYP-1901.

Nancy Lurker, Executive Vice-Chair of the Board of EyePoint Pharmaceuticals, discussed the subgroup analyses of the Phase 1 DAVIO Trial of EYP-1901 with our team at the 2023 ASRS annual meeting.

Video Transcript

Editor's note - This transcript has been edited for clarity.

Nancy Lurker:

Hi, I'm Nancy Lurker, the Executive Vice-Chair of the Board of EyePoint Pharmaceuticals. Dr J. Duker, our CEO, sends his regards [as] he was not able to make the meeting. We're very excited about some of the data that we presented at OIS on Thursday, here, ahead of ASRS in Seattle. In that presentation, we presented, most importantly, an interim safety update of masked data of our DAVIO 2 for wet AMD, double masked study, with an EYELA control.

That's 160 patients fully enrolled, and we expect the top line data read out to be this December. The goal of that study is to be able to show equal BCBA, non inferior, to EYELA and, most importantly, be able to show time to first supplementation, as well as total treatment burden reduction. Our goal is to be able to get a majority of patients out to 6 months or beyond with a tyrosine kinase inhibitor in our proven Durasert drug-delivery technology. Now, what we presented isn't this interim masked safety update in this 160 patient trial. What we're happy to report is that there were no drug-related, serious adverse events.

There were 2, but not drug-related. 1 was in the fellow eye [and] was a retinal hemorrhage. The other was a retinal detachment after the second aflibercept injection, but before either EYP-1901 or sham was injected. So far, the data looked very clean. Secondarily, we also presented patient demographics comparing our Phase 1 DAVIO study, which was a safety study of 17 patients, versus the DAVIO 2 study. What we have to show is that the patient demographics. The patients in DAVIO 1, because that was an all-comers trial, were sicker.

They had higher CST, 299 [in DAVIO 1] versus 266 in DAVIO 2. Vision was slightly worse, 70, 66 in DAVIO 1 versus 74 in DAVIO 2. We actually expect that we're getting a more representation patient population in DAVIO 2, the typical patient broad-based that you normally see in your practices. We're excited about where we are. We're looking forward to our update and top line readout in December of this year.

Related Videos
ARVO 2024: Andrew D. Pucker, OD, PhD on measuring meibomian gland morphology with increased accuracy
 Allen Ho, MD, presented a paper on the 12 month results of a mutation agnostic optogenetic programme for patients with severe vision loss from retinitis pigmentosa
Noel Brennan, MScOptom, PhD, a clinical research fellow at Johnson and Johnson
ARVO 2024: President-elect SriniVas Sadda, MD, speaks with David Hutton of Ophthalmology Times
Elias Kahan, MD, a clinical research fellow and incoming PGY1 resident at NYU
Neda Gioia, OD, sat down to discuss a poster from this year's ARVO meeting held in Seattle, Washington
Eric Donnenfeld, MD, a corneal, cataract and refractive surgeon at Ophthalmic Consultants of Connecticut, discusses his ARVO presentation with Ophthalmology Times
John D Sheppard, MD, MSc, FACs, speaks with David Hutton of Ophthalmology Times
Paul Kayne, PhD, on assessing melanocortin receptors in the ocular space
Osamah Saeedi, MD, MS, at ARVO 2024
© 2024 MJH Life Sciences

All rights reserved.